Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.
Ceftaroline fosamil is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). This study evaluated the frequency and antimicrobial susceptibility of organisms isolated from patients hospitalised with community-acquired (CA) SSSI in Europe, the Asia-Pacific region (APAC) and Latin America (LATAM). Isolates (n=5120) were consecutively collected from patients hospitalised with CA-SSSI in 2014-2016 from 63 medical centres in 41 nations, stratified as Western Europe (20 centres/10 nations), Eastern Europe and the Mediterranean region (E-EUR; 16 centres/12 nations), APAC (16 centres/10 nations) and LATAM (11 centres/9 nations). Isolates obtained from outpatients or <48h after hospitalisation were considered CA. Organisms were tested for susceptibility by reference broth microdilution in a central laboratory. S. aureus was the most common CA-SSSI organism in all regions, except LATAM, and represented 43.3% of the overall collection. MRSA rates varied from 15.8% (E-EUR) to 21.4% (APAC), being 18.5% overall. In general, 98.9% of S. aureus and 94.2% of MRSA isolates were susceptible to ceftaroline, with 99.5% of MRSA isolates inhibited at ≤2mg/L (0.5% resistant). Escherichia coli (14.2%) and β-haemolytic streptococci (BHS) (8.2%) ranked second and third overall, respectively, with wide regional variation. BHS isolates were highly susceptible to ceftaroline (highest MIC, 0.03mg/L), but exhibited decreased susceptibility to tetracycline and erythromycin. The frequency and antimicrobial susceptibility of CA-SSSI bacteria varied broadly by geographic region. Ceftaroline exhibited potent activity against S. aureus (including MRSA), BHS and ceftriaxone-susceptible Enterobacterales isolates.